-
Mashup Score: 2
MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM) – Full Text View.
Source: classic.clinicaltrials.govCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 11Managing the Challenges of Paying for Gene Therapies - ICER - 2 day(s) ago
This paper explains potential reforms to white bagging, brown bagging, and site of service policies. Learn more.
Source: icer.orgCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 5ODAC Approves MRD End Point in Multiple Myeloma Trials - 4 day(s) ago
Minimal residual disease can now be considered an end point in trials leading to accelerated approvals by the FDA for multiple myeloma.
Source: www.cancernetwork.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 5ODAC Approves MRD End Point in Multiple Myeloma Trials - 4 day(s) ago
Minimal residual disease can now be considered an end point in trials leading to accelerated approvals by the FDA for multiple myeloma.
Source: www.cancernetwork.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 9Labcorp to acquire Invitae’s assets for $239M - 7 day(s) ago
William Blair analyst Andrew Brackmann said Labcorp is being aggressive in its M&A strategy, after announcing last month it would buy several of Bioreference Health’s testing businesses.
Source: www.medtechdive.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 5ODAC Approves MRD End Point in Multiple Myeloma Trials - 11 day(s) ago
Minimal residual disease can now be considered an end point in trials leading to accelerated approvals by the FDA for multiple myeloma.
Source: www.cancernetwork.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 14Myosin inhibitor reverses hypertrophic cardiomyopathy in genotypically diverse pediatric iPSC-cardiomyocytes to mirror variant correction - 12 day(s) ago
Kinnear et al. demonstrate the ability of myosin inhibitors to restore function in pediatric hypertrophic cardiomyopathy patient and gene-edited iPSC-cardiomyocytes harboring myosin variants. From monogenic to digenic to biallelic variants, these inhibitors outperform non-targeted drugs, signaling a promising path for myosin-targeted therapies and an urgent call for clinical trials in children.
Source: www.cell.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 14South Waterfront Ronald McDonald House at the OHSU Rood Family Pavilion · 3410 S Bond Ave, Portland, OR 97239 - 12 day(s) ago
★★★★★ · Non-profit organization
Source: www.google.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 5ODAC Approves MRD End Point in Multiple Myeloma Trials - 16 day(s) ago
Minimal residual disease can now be considered an end point in trials leading to accelerated approvals by the FDA for multiple myeloma.
Source: www.cancernetwork.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 5ODAC Approves MRD End Point in Multiple Myeloma Trials - 20 day(s) ago
Minimal residual disease can now be considered an end point in trials leading to accelerated approvals by the FDA for multiple myeloma.
Source: www.cancernetwork.comCategories: General Medicine News, CardiologistsTweet
More trials in #ATTR cardiomyopathy MAGNITUDE is a 765 patient trial randomizing patients with ATTR CM to NTLA-2001 vs placebo https://t.co/UtFlaymGj3 #CardioTwitter https://t.co/CthPYiklqd